This year's award marks 30 years since clinicians first used ECP to successfully treat chronic graft versus host disease (cGvHD).1 In recognition of this important milestone, this year's $75,000 grant was dedicated to advancing research...
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
The Therakos company does not review or control the content of non-Therakos company websites. Therakos privacy procedures do not apply to the owners of a non-Therakos Group websites.